What We're Reading: Page 68
Industry reads hand-picked by our editors
Dec 06, 2023
Dec 05, 2023
-
The Wall Street Journal
The Executives Who Could Be Johnson & Johnson’s Next CEO
-
Reuters
Blackstone explores sale of Anthos Therapeutics - sources
-
Axios
Study finds sharp drop in FDA inspections since pandemic began
-
MIT Technology Review
I received the new gene-editing drug for sickle cell disease. It changed my life.
Dec 04, 2023
-
The Wall Street Journal
The Opioid Victims Who Won’t Sign Off on Purdue’s $6 Billion Settlement
-
FirstWord Pharma
Roche hits snag in clinical programme for MS hopeful fenebrutinib
-
Reuters
AstraZeneca, AI biologics firm Absci tie up on cancer drug
-
CNN
Biden’s prescription for 2024 turnaround will include major health care focus
Dec 01, 2023
-
Reuters
Maker of Wegovy, Ozempic showers money on U.S. obesity doctors
-
MIT Technology Review
How will the Broad Institute use its CRISPR patent now that the first cure is here?
-
The Hill
Texas AG Paxton suing Pfizer for attempted censorship, ‘misrepresenting’ COVID-19 vaccination
-
The Wall Street Journal
The Fight Against Frown Lines Has Never Been More Complicated
Nov 30, 2023
Nov 29, 2023
-
Bloomberg
Bayer M&A Simulation Game Casts Doubt on Any Quick Fixes
-
San Francisco Business Times
Personalized approach to Alzheimer’s Disease draws documentary, criticism
-
ApexOnco
Argenx’s efforts to Advance fall flat
Nov 28, 2023
-
LifeSciVC
Darkest Before Dawn: A Story Of Biotech Optimism In A Tough Market
-
Reuters
Lilly’s Mounjaro leads to more and faster weight loss than Novo obesity drug, data analysis finds
-
Axios
Biden looks to boost domestic drug manufacturing amid shortages
-
USA Today
Medical treatment designed for one patient may be the future for many
Previous
